Clinical Insights: Role of Amivantamab in Head and Neck Cancer
June 2, 2026
Key Points
-
First-line treatment for recurrent metastatic head and neck cancer is based on pembrolizumab with or without chemotherapy, as established by KEYNOTE-048.
-
Therapeutic options after progression on immunotherapy remain limited and are associated with modest response rates and poor durability.
-
OrigAMI-4 demonstrates encouraging activity for amivantamab, with a response rate of 42% in heavily pretreated patients and a complete response rate of approximately 15%.
Cohosts of the Oncology Brothers podcast—Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center—moderated a Clinical Insights discussion on metastatic head and neck cancer coinciding with the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. They were joined by Barbara Burtness, MD, of Yale School of Medicine; Ari Rosenberg, MD, of the University of Chicago; Paul Swiecicki, MD, of University of Michigan Health; and Jessica Geiger, MD, of Cleveland Clinic. The panel focused on current standards in recurrent metastatic disease, persistent unmet needs after immunotherapy, and emerging data surrounding EGFR-MET bispecific strategies.
Current Standards and the Post-Immunotherapy Treatment Gap
Describing the frontline landscape, Dr. Geiger emphasized that pembrolizumab-based therapy—either as monotherapy or combined with chemotherapy per KEYNOTE-048—remains the foundation of treatment for recurrent metastatic head and neck squamous cell carcinoma. Selection between monotherapy and chemoimmunotherapy is driven by PD-L1 status, disease burden, and patient fitness, but immunotherapy has clearly redefined the initial approach compared with the pre–checkpoint inhibitor era.
However, both Dr. Geiger and Dr. Rosenberg underscored that disease progression after immunotherapy remains a major clinical challenge. Once patients fail frontline PD-1–based strategies, options are largely limited to single-agent chemotherapy or cetuximab, both of which yield modest response rates and limited durability. Dr. Rosenberg highlighted that this setting is also defined by substantial symptom burden, including pain, dysarthria, and progressive functional decline. From a clinical practice standpoint, Dr. Swiecicki noted, patients are increasingly informed and proactive, often entering discussions with awareness of trials, biomarkers, and evolving therapeutic options.
EGFR-MET Biology and the Rationale for Dual-Targeted Therapy
Dr. Burtness provided key insight into resistance pathways, explaining that although EGFR inhibition with cetuximab has long been a therapeutic backbone, tumors frequently bypass this blockade through parallel signaling networks. These include HER family activation and MET-driven signaling, which together sustain downstream proliferative and survival pathways even in the presence of EGFR inhibition. Within this framework, MET activation plays a particularly important role by promoting epithelial-to-mesenchymal transition and reinforcing adaptive resistance. Dr. Burtness highlighted that this biology has driven interest in dual-targeted approaches that can simultaneously inhibit EGFR and MET, with amivantamab representing a leading example.
Dr. Rosenberg emphasized that although bispecific antibodies like amivantamab are familiar in hematologic malignancies, their application in solid tumors represents a distinct therapeutic paradigm, particularly given the absence of classical cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome signals in this context.
OrigAMI-4 Clinical Activity and Implications for Later-Line Therapy
Dr. Geiger discussed clinical data from OrigAMI-4 as a potentially practice-shifting signal in heavily pretreated, HPV-unrelated recurrent metastatic head and neck cancer. In cohort 1 of the trial, which included a substantial proportion of patients treated in the third line or beyond, single-agent subcutaneous amivantamab demonstrated a confirmed objective response rate of 42%, with approximately 15% of patients achieving a complete response, a marked improvement over historical benchmarks in this setting.
Importantly, Dr. Burtness noted that nearly half of enrolled patients were receiving third-line therapy, underscoring the refractory nature of the population. Despite this, responses were described as rapid and durable, with median overall survival exceeding 12 months—outcomes that compare favorably to historical cetuximab-based therapy, in which response rates are closer to 20% to 25%.
Dr. Rosenberg emphasized that these findings are particularly relevant in HPV-unrelated disease, which carries a worse prognosis and fewer effective treatment options than HPV-associated disease. Across the panel, there was consensus that although these data require confirmation, the magnitude and consistency of responses suggest meaningful biologic activity in a population with historically limited therapeutic options.
Toxicity Management, Clinical Integration, and Earlier-Line Strategies
Safety and tolerability were a major focus of discussion, with Dr. Rosenberg and Dr. Swiecicki highlighting the advantages of subcutaneous administration, which appears to substantially reduce infusion-related reactions compared with intravenous formulations. Dr. Swiecicki and Dr. Geiger both emphasized that expected toxicities remain manageable with established EGFR-inhibitor frameworks, including dermatologic reactions, hypomagnesemia, hypoalbuminemia, and edema. Because patients with head and neck cancer are often at risk of nutritional compromise and lymphatic dysfunction, proactive supportive care—including skin prophylaxis and nutritional monitoring—was described as essential to keeping patients on treatment.
Collectively, the panel agreed that while immunotherapy remains foundational, EGFR-MET bispecific approaches such as amivantamab may meaningfully reshape both sequencing and outcomes if ongoing randomized data confirm these early signals.